Olympus To Step Up Endoscope Business In China
This article was originally published in PharmAsia News
Top endoscope maker Olympus recently disclosed that its capsule endoscope is currently under review with China's State FDA and is expected to enter the China market as early as late this year. The capsule endoscope will represent a milestone product for the firm's health care business to open up China's market. Even though digital cameras and endoscopes make up one-third each of Olympus' business, the company is only known in China for its cameras. Thus, the firm's primary and most pressing task is to build up brand awareness in the country. To quickly occupy the market, Olympus has established main branches in Beijing, Shanghai and Guangzhou as well as a network of 31 representative offices across the country. It will next target gastroenterology and general surgery as two focus areas. (Click here for more - Chinese Language)
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.